SCHEMBL1423922

SCHEMBL1423922

Oc1c(F)cccc1-c1ccncc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
LMNA P02545 2/20 0.46
RPS6KA3 P51812 5/20 0.44
PKM P14618 1/20 0.44
KMT2A Q03164 1/20 0.44
MAPT P10636 2/20 0.41
ALDH1A1 P00352 1/20 0.41
TP53 P04637 1/20 0.41
MAPK10 P53779 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HSD17B10 Q99714 1/20 0.41
PIK3CD O00329 1/20 0.41
JAK2 O60674 1/20 0.40
JAK1 P23458 1/20 0.40
TYK2 P29597 1/20 0.40
HTT P42858 1/20 0.40
NOD2 Q9HC29 1/20 0.40
CDC7 O00311 1/20 0.39
CA1 P00915 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27981067 0.85 MAPT (0.48) NPC1RAB9ALMNARPS6KA3MAPT
SCHEMBL2938278 0.81 HDAC4 (0.54) RAB9ALMNARPS6KA3ALDH1A1HSD17B10
SCHEMBL3637569 0.79 NPC1 (0.46) NPC1RAB9ALMNAPKMKMT2A
SCHEMBL2649506 0.79 NPC1 (0.58) NPC1RAB9ALMNAPKMKMT2A
SCHEMBL30418017 0.79 NPC1 (0.58) NPC1RAB9ALMNAPKMKMT2A
SCHEMBL20034246 0.78 ALB (0.50) LMNAKMT2AMAPTALDH1A1HSD17B10
SCHEMBL2649168 0.76 LMNA (0.58) NPC1RAB9ALMNAPKMKMT2A
SCHEMBL1423704 0.76 ALDH1A1 (0.50) NPC1RAB9ALMNAMAPTALDH1A1
SCHEMBL1423606 0.76 IDO1 (0.51) NPC1RAB9ALMNARPS6KA3MAPT
Hydrochloric Acid SCHEMBL7232119 0.74 HSD17B1 (0.41) NPC1AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110224204-A1 DI-SUBSTITUTED PHENYL COMPOUNDS ENVIVO PHARMACEUTICALS, INC. 2011-09-15 US disclosed
CN-102131798-A Di-substituted phenyl compounds used as inhibitors of phosphodiesterase 10 ENVIVO PHARMACEUTICALS INC 2011-07-20 CN disclosed
EP-2297131-A2 DI-SUBSTITUTED PHENYL COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS Envivo Pharmaceuticals, Inc. (US) 2011-03-23 EP disclosed
WO-2009158467-A2 DI-SUBSTITUTED PHENYL COMPOUNDS ENVIVO PHARMACEUTICALS, INC. (US) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224204-A1 DI-SUBSTITUTED PHENYL COMPOUNDS PDE10A, PDE1A, PDE12 NPC1 2142/4885RAB9A 597/4885LMNA 3685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.